

Nakano M et al.

1 **Title:**

2 Cell-type-specific transcriptome architecture underlying the establishment and exacerbation of  
3 systemic lupus erythematosus

4  
5 **Authors:**

6 Masahiro Nakano<sup>1,2</sup>, Mineto Ota<sup>1,3</sup>, Yusuke Takeshima<sup>1</sup>, Yukiko Iwasaki<sup>1</sup>, Hiroaki Hatano<sup>1,4</sup>, Yasuo  
7 Nagafuchi<sup>1,3</sup>, Takahiro Itamiya<sup>1</sup>, Junko Maeda<sup>1</sup>, Ryochi Yoshida<sup>1</sup>, Saeko Yamada<sup>1</sup>, Aya Nishiwaki<sup>1</sup>,  
8 Haruka Takahashi<sup>1</sup>, Hideyuki Takahashi<sup>1</sup>, Yuko Akutsu<sup>1</sup>, Takeshi Kusuda<sup>1</sup>, Hiroyuki Suetsugu<sup>5,6,7</sup>, Lu  
9 Liu<sup>8,9</sup>, Kwangwoo Kim<sup>10,11</sup>, Xianyong Yin<sup>8,9,12</sup>, So-Young Bang<sup>13,14</sup>, Yong Cui<sup>15</sup>, Hye-Soon Lee<sup>13,14</sup>,  
10 Hirofumi Shoda<sup>1</sup>, Xuejun Zhang<sup>8,9</sup>, Sang-Cheol Bae<sup>13,14</sup>, Chikashi Terao<sup>5,16,17</sup>, Kazuhiko Yamamoto<sup>1,2</sup>,  
11 Tomohisa Okamura<sup>1,3</sup>, Kazuyoshi Ishigaki<sup>1,4\*</sup>, and Keishi Fujio<sup>1\*</sup>

12  
13 **Affiliations:**

14 <sup>1</sup> Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo,  
15 Tokyo, Japan

16 <sup>2</sup> Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Kanagawa,  
17 Japan

18 <sup>3</sup> Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine,  
19 the University of Tokyo, Tokyo, Japan

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Nakano M et al.

20 <sup>4</sup> Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Kanagawa,  
21 Japan

22 <sup>5</sup> Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical  
23 Sciences, Tokyo, Japan

24 <sup>6</sup> Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University,  
25 Fukuoka, Japan

26 <sup>7</sup> Department of Orthopaedic Surgery, Hamanomachi hospital, Fukuoka, Japan

27 <sup>8</sup> Department of Dermatology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China

28 <sup>9</sup> Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China

29 <sup>10</sup> Department of Biology, Kyung Hee University, Seoul, Korea

30 <sup>11</sup> Department of Biomedical and Pharmaceutical Sciences, Kyung Hee University, Seoul, Korea

31 <sup>12</sup> Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor,  
32 Michigan, USA

33 <sup>13</sup> Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea

34 <sup>14</sup> Hanyang University Institute for Rheumatology Research, Seoul, Korea

35 <sup>15</sup> Department of Dermatology, China-Japan Friendship Hospital, Beijing, China

36 <sup>16</sup> Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan

37 <sup>17</sup> The Department of Applied Genetics, The School of Pharmaceutical Sciences, University of  
38 Shizuoka, Shizuoka, Japan

39

Nakano M et al.

40 **Correspondence:**

41 Kazuyoshi Ishigaki, MD, PhD

42 Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, 1-7-22

43 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.

44 kazuyoshi.ishigaki@riken.jp.

45

46 Keishi Fujio, MD, PhD

47 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-

48 3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

49 FUJIOK-INT@h.u-tokyo.ac.jp.

50

Nakano M et al.

51 **Abstract**

52 Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease involving  
53 multiple immune cells. A major hurdle to the elucidation of SLE pathogenesis is our limited  
54 understanding of dysregulated gene expression linked to various clinical statuses with a high cellular  
55 resolution. Here, we conducted a large-scale transcriptome study with 6,386 RNA sequencing data  
56 covering 27 immune cell types from 159 SLE and 89 healthy donors. We first profiled two distinct cell-  
57 type-specific transcriptomic signatures: disease-state and disease-activity signatures, reflecting  
58 disease establishment and exacerbation, respectively. We next identified candidate biological  
59 processes unique to each signature. This study suggested the clinical value of disease-activity  
60 signatures, which were associated with organ involvement and responses to therapeutic agents such  
61 as belimumab. However, disease-activity signatures were less enriched around SLE risk variants  
62 than disease-state signatures, suggesting that the genetic studies to date may not well capture  
63 clinically vital biology in SLE. Together, we identified comprehensive gene signatures of SLE, which  
64 will provide essential foundations for future genomic, genetic, and clinical studies.

65

## 66 **Introduction**

67 Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that involves multiple  
68 immune cell types and pathways<sup>1,2</sup>. SLE has a broad spectrum of clinical manifestations such as skin  
69 rashes, arthritis and nephritis, and the disease course is generally unpredictable<sup>3</sup>. This  
70 heterogeneous nature has hampered a better understanding of SLE pathogenesis and the  
71 development of effective therapeutic agents<sup>4,5</sup>. To date, only two biologics have been approved for  
72 SLE, belimumab (BLM) and anifrolumab, monoclonal antibodies against B cell-activating factor  
73 (BAFF) and type I interferon (IFN) receptor subunit 1, respectively<sup>6-9</sup>.

74 To detect biomarkers and therapeutic targets for SLE, several studies on bulk whole-blood or  
75 peripheral blood mononuclear cell (PBMC) transcriptomes have revealed some key gene signatures  
76 related to IFN signaling, granulocytes, and plasma cells<sup>10-16</sup>. However, these studies have suffered  
77 from one critical limitation: the results were biased by the abundance of various immune cell  
78 populations in the analyzed samples, which complicates the identification of any cell-type-specific  
79 disease-relevant signatures<sup>17</sup>. Therefore, recent studies applied single-cell RNA sequencing (scRNA-  
80 seq), a powerful technology to improve cellular resolution, to PBMCs, skin and kidney samples from  
81 SLE patients and have successfully identified several cell subpopulations crucial for lupus  
82 pathogenesis<sup>18-20</sup>. However, since these scRNA-seq studies of SLE were limited by sparse  
83 expression information and small sample sizes (around 30 cases), they were not well-powered to  
84 capture comprehensive transcriptome abnormality related to different clinical manifestations. These

Nakano M et al.

85 limitations could be overcome by a large-scale bulk transcriptome study with finely sorted cell  
86 populations.

87 SLE etiology has both genetic and environmental components<sup>1-3</sup>. Researchers have  
88 conducted large-scale genome-wide association studies (GWASs) for SLE<sup>21-23</sup>, identifying more than  
89 one hundred risk loci. Combined with omics data mostly from healthy individuals, researchers  
90 attempted to interpret the genetic etiology and have identified potential causal roles of IFN, Toll-like  
91 receptor signaling and immune complexes<sup>24-26</sup>. However, these studies have not thoroughly  
92 investigated the complex interactions between risk variants and the transcriptome dysregulation seen  
93 in SLE patients. Such investigations hold the promise to elucidate the complex pathogenesis of SLE.

94 To address these issues, we conducted a large-scale transcriptome study of 6,386 bulk RNA  
95 sequencing (RNA-seq) data including 27 purified immune cell types in peripheral blood that  
96 encompassed almost every type of immune cell (**Fig. 1**). We recruited 136 SLE patients with various  
97 disease activities and clinical presentations (22 among them were re-evaluated after BLM treatment;  
98 **Methods**) and 89 healthy volunteers in the Immune Cell Gene Expression Atlas from the University  
99 of Tokyo (ImmuNexUT) cohort<sup>27</sup> (discovery dataset). Using multiple approaches, we investigated cell-  
100 type-specific transcriptome dysregulation and classified them into two categories: disease-state and  
101 disease-activity signatures. Furthermore, we deployed these signatures to five main topics of  
102 downstream analyses: i) replication, ii) biological interpretation, iii) diverse organ involvement, iv) pre-  
103 and post-treatment comparison, and v) the SLE-GWAS signals (**Fig. 1**). Overall, our large-scale and

Nakano M et al.

104 comprehensive investigation uncovered the molecular basis underlying the clinical heterogeneity of

105 SLE with a fine resolution of cell-type-specificity.

106

107 **Results**

108 **Overview of gene expression patterns in the ImmuneNexUT cohort.**

109 Our dataset included 27 finely sorted immune cell types: CD4<sup>+</sup> T cells, nine subsets; CD8<sup>+</sup> T cells,  
110 four subsets; NK cells, one subset; B cells, five subsets; monocytes, four subsets; dendritic cells, two  
111 subsets; and neutrophils, two subsets (**Fig. 1, left; Supplementary Table 1**). We recruited 248  
112 donors in total. Among them, 136 unique SLE patients and 89 healthy controls (HC) were included in  
113 the discovery dataset; the rest included 22 post-BLM patients (**Methods**). Compared with previous  
114 studies with fine resolution transcriptomes<sup>18–20</sup>, larger sample size with multiple clinical statuses (e.g.,  
115 disease activity, organ involvement, and treatment profiles) is an advantage of our cohort  
116 (**Supplementary Note; Supplementary Table 2**). At enrollment, 30 patients (22.1%) in the discovery  
117 dataset had high disease activity (HDA; SLEDAI-2K<sup>28</sup> ≥ 9), while 31 (22.8%) patients were inactive  
118 (SLEDAI-2K = 0). Forty one (30.1%), 27 (19.9%) and 30 (22.1%) patients had mucocutaneous,  
119 musculoskeletal, and renal activity, respectively<sup>29</sup>.

120 To understand the highly complex transcriptomic signatures in our datasets (16,000 genes  
121 and 6,386 samples from 248 donors; **Extended Data Fig. 1a; Methods**), we first aimed to project all  
122 samples in low dimensional spaces. Principal component analysis (PCA) showed that the samples  
123 from the same cell type clustered together followed by the same cell lineage (**Extended Data Fig.**  
124 **1b**); this pattern became more evident in the uniform manifold approximation and projection (UMAP)  
125 (**Extended Data Fig. 1c**). We also confirmed that batch effects were successfully removed in all cell  
126 types (**Extended Data Fig. 2a-b**).



Nakano M et al.

127 IFN-related gene (IRG) expression is a hallmark signature of SLE<sup>30–32</sup>. To explicitly quantify  
128 transcriptome patterns well-established for lupus, we utilized 100 IRGs reported in a recent PBMC  
129 scRNA-seq study having the highest cellular resolution<sup>20</sup> (**Fig. 2a**). The cell-type- and disease-  
130 specific IRG expression patterns were globally consistent with those in the original publication: e.g.,  
131 upregulated *CXCL10* and *IFITM3* expression (G5) in lupus CD16-positive monocytes (CD16p Mono)  
132 and upregulated *IRF7* and *PARP10* expression (G8) in plasmacytoid dendritic cells (pDC).  
133 Additionally, about half (n=54) of IRGs showed the highest expression in SLE neutrophil-lineage  
134 cells, which were not evaluated in the previous scRNA-seq studies of SLE<sup>18–20</sup>. Together, our  
135 transcriptomic data exhibited the expected cell-type-specific patterns and recapitulated previously  
136 established IRG signatures.

137

### 138 **Disease activity is a major source of variation in the within-SLE transcriptome data.**

139 To explore the source of the transcriptomic variations in the discovery dataset, we conducted PCA  
140 within each cell type and evaluated the distribution of samples in the PCA space (**Supplementary**  
141 **Data 1**). The top PCs differentiated SLE patients from HC in all cell types, indicating widespread  
142 transcriptome perturbations in SLE immune cells (**Fig. 2b; Extended Data Fig. 3**). In addition, gene  
143 expression profiles within patients showed higher variation than those within HC (**Fig. 2c; Methods**).

144 We further evaluated how the transcriptome variations reflected the heterogeneous clinical  
145 statuses. We first confirmed that PC1-7 is the minimum set to associate the transcriptome with the  
146 clinical parameters in the discovery dataset and utilized PC1-7 scores for subsequent analyses

Nakano M et al.

147 **(Supplementary Note; Supplementary Fig. 1a-c; Supplementary Table 3)**. We then quantified the  
148 contribution of clinical parameters to the within-SLE variation using weighted variance partitioning  
149 analysis (**Fig. 2d; Methods**). Importantly, this analysis revealed that disease activity had the largest  
150 contribution to the total variation within SLE in almost all cell types (7.6% on average), around 2.9-  
151 fold larger than the treatment contribution.

152

### 153 **SLE disease-state and activity signatures.**

154 Motivated by the fact that both case-control differences and disease activity substantially contributed  
155 to the whole transcriptome architecture, we next deployed a supervised approach to the discovery  
156 dataset to identify two transcriptomic signatures for each cell type: i) disease-state signature genes,  
157 defined as differentially expressed genes (DEGs, false discovery rate [FDR] < 0.05) between inactive  
158 SLE and HC, which reflect the biology of disease establishment, and ii) disease-activity signature  
159 genes, defined as DEGs between HDA and inactive SLE, which reflect the biology of disease  
160 exacerbation (**Fig. 1, middle; Fig. 3a; Extended Data Fig. 4a**). We detected comparable numbers of  
161 DEGs between these two comparisons (on average, 2,098 disease-state and 2,114 disease-activity  
162 signature genes; **Extended Data Fig. 4b; Supplementary Data 2-3**). We conducted replication  
163 analysis using independent cohorts<sup>33-35</sup> (**Fig. 1, i**) and confirmed the robustness of both signatures by  
164 showing their high replicability (one-sided sign test, Bonferroni-corrected  $P < 0.05$ ; **Supplementary**  
165 **Note; Supplementary Table 4; Extended Data Fig. 5a-b**).

Nakano M et al.

166 To examine the specificity of these signatures, we first compared them within each cell type.  
167 We calculated the Jaccard similarity index in each cell type to quantify the shared genes between  
168 signatures (**Fig. 3a**); we considered that a gene was shared when it was included in both signatures  
169 with a concordant sign (**Methods**). Based on the proportion of DEGs and Jaccard index, we found  
170 three different transcriptome perturbation patterns (**Methods**): disease-state dominant pattern, e.g.,  
171 B-lineage cells and naive CD4/8+ T cells, disease-activity dominant pattern, e.g., plasmablasts, and  
172 shared pattern, e.g., monocyte- and neutrophil-lineage cells (**Fig. 3a-b; Extended Data Fig. 4b**).  
173 When we evaluated the similarity based on the correlation of log fold changes (logFC) for both  
174 signatures, we observed consistent patterns (**Extended Data Fig. 4c**).

175 We next compared signature genes across different cell types and confirmed cell-type-  
176 specific and shared components. Around 20% and 30% of signature genes were detected in only one  
177 cell type and lineage, respectively (**Fig. 3c**). To understand the distribution of the shared components  
178 across cell types, we calculated the Jaccard index (**Fig. 3d**) and correlation (**Extended Data Fig. 4d**).  
179 Globally, we detected higher similarity within the same cell-lineage than in different lineages in both  
180 signatures. However, we found a clear discrepancy between the signatures; high similarity among T  
181 helper 1 (Th1) and cytotoxic lymphocytes (natural killer [NK] and CD8+ memory T-lineage cells)<sup>36</sup>  
182 was observed only in activity signatures (blue square in **Fig. 3d** and **Extended Data Fig. 4d**). These  
183 gaps indicated the presence of gene expression patterns specific to HDA patients in these cell types.  
184 Thus, our dataset captured distinct transcriptome perturbations in the disease establishment and  
185 exacerbation phases in a cell-type-specific manner.

186

187 **Cell-type-specific biology in disease establishment and exacerbation.**

188 To understand the SLE biology in disease establishment and exacerbation, we next sought to  
189 interpret disease-state and activity signature genes in each cell type using multiple external  
190 databases (**Fig. 1, ii**).

191 First, we focused on 137 genes encoding cytokines (**Supplementary Table 5**), the key  
192 regulators of immune responses and potential drug targets in autoimmune diseases<sup>37</sup>. Fifty-one  
193 genes were upregulated in at least one signature, consistent with previous studies: *IFNG* in Th1, NK,  
194 and CD8+ memory T-lineage cells<sup>38,39</sup>, and *TNFSF13B*, encoding BAFF, especially in DC-,  
195 monocyte-, and neutrophil-lineage cells with the highest expression<sup>40</sup> (**Fig. 4a, top**). Among these  
196 genes, we identified 21 and 17 that were upregulated specifically in one cell-lineage in disease-state  
197 and activity signatures, respectively; representative examples of activity signatures included *IL12A/B*  
198 in switched memory B cells (SM B), *IL1B* in monocyte-lineage, *CCL2/8* in classical monocyte (CL  
199 mono), *IL18/TNFSF15* in neutrophil-lineage cells, and *IL21* and *CXCL13* in Th1 (**Fig. 4a, top**).  
200 Among them, *IL21* and *CXCL13*, critical genes to support B cell antibody production<sup>41,42</sup>, are  
201 especially intriguing. Although previous studies reported follicular helper T cells (Tfh) as the major  
202 source of *IL21* and *CXCL13*<sup>43</sup>, Th1 showed a more dynamic increase than Tfh, especially in the  
203 activity signatures (**Fig. 4a, bottom**).

204 Next, we inferred activities of transcription factors (TF), essential regulators of immune  
205 function, based on the expression of TF-downstream genes (**Methods**). Among 61,182 total tests

Nakano M et al.

206 (1,133 TF annotations × 27 cell types × two signatures), we observed 1,228 significant enrichments  
207 for 299 annotations (FDR < 0.05; one-sided Fisher's exact test; **Supplementary Table 6**). Among  
208 them, disease-activity signatures showed more enrichments (862 enrichments [70.2%]; **Fig. 4b, top**).  
209 These results suggested underappreciated pathogenic roles of TFs in SLE exacerbation. We here  
210 highlight two such examples (**Fig. 4b, middle**). First, cell cycle regulators including E2F-families  
211 showed strong enrichment in activity signatures of Th1, NK, CD8+ memory T-lineage cells, and  
212 plasmablasts, indicating that these cells are probably proliferating in active SLE patients. Upregulated  
213 cell cycle regulation might be driving the high similarities between these cell types in disease-activity  
214 signatures (**Fig. 3d, right**). Second, *BACH2* showed significant enrichment in disease-activity  
215 signatures for myeloid-lineage cells. Intriguingly, *BACH2* also showed strong enrichment in  
216 lymphocytes, consistent with previous studies<sup>44,45</sup>, but primarily in disease-state signatures. These  
217 results demonstrated that an identical gene regulatory machinery can exert a pathogenic effect in  
218 different cell types depending on the disease phases (**Fig. 4b, bottom**).

219 Lastly, we also performed pathway enrichment analyses to examine multiple biological  
220 processes underlying lupus pathogenesis (**Methods**). Among 32,292 total tests for 598 pathways, we  
221 observed 735 and 315 significant enrichments for disease-state and activity, respectively (FDR <  
222 0.05; one-sided Fisher's exact test; **Extended Data Fig. 6a; Supplementary Table 7-8**). We  
223 confirmed the enrichment of established pathways such as complement activation<sup>46,47</sup>  
224 (**Supplementary Note; Extended Data Fig. 6b**). Intriguingly, we found different enrichment patterns  
225 between the signatures in metabolism- and cellular process-related KEGG pathways (**Fig. 4c, left;**

Nakano M et al.

226 **Extended Data Fig. 6c; Methods**). For example, oxidative phosphorylation signaling was enriched  
227 especially in B-lineage cells for disease-state whereas it was enriched in Th1 and effector memory  
228 CD8+ T cells (EMCD8) for disease-activity signatures (**Fig. 4c, right**). TCA cycle signaling was  
229 enriched in disease-activity signatures of Th1 and CD8+ memory T-lineage cells. Ribosome  
230 pathways were enriched only in disease-activity signatures. Cell cycle activation was enriched  
231 predominantly in disease-activity signatures of Th1, NK, CD8+ memory T-lineage cells, and  
232 plasmablasts. Although ribosome and cell cycle pathways were already described as disease activity-  
233 related pathways in previous bulk whole-blood studies<sup>13,16</sup>, our analysis clarified the precise cell-type  
234 origin of these pathways. Furthermore, we extended our view to previously underappreciated  
235 pathways such as immunometabolism, describing disease establishment and exacerbation phases  
236 separately.

237

### 238 **Cell-type-specific contribution to organ involvement in SLE.**

239 To resolve the complex relationships between transcriptome dysregulation and clinical heterogeneity  
240 in SLE, we leveraged a PC-based unsupervised approach (**Fig. 1, iii**). In the hierarchical clustering of  
241 225 unique individuals using all 189 PCs (= 7 PCs × 27 cell types), HC were clearly separated from  
242 patients; in addition, HDA patients with multiple organ complications were clustered together (**Fig. 5a;**  
243 **Extended Data Fig. 7a**).

244 Compared with the approach using thousands of signature genes, the PC-based approach is  
245 better at representing whole transcriptome architecture with a small number of parameters. To

Nakano M et al.

246 understand the biological significance of each PC, we defined two categories of PCs as in the  
247 discussion of signature genes: i) disease-state PCs, separating inactive SLE and HC, and ii) disease-  
248 activity PCs, separating HDA and inactive SLE (FDR < 0.05; **Fig. 5b; Supplementary Table 3;**  
249 **Methods**). Among 189 PCs, we identified 37 disease-state PCs and 25 disease-activity PCs; among  
250 them, nine PCs were classified into both (**Extended Data Fig. 7b**). When we projected the data from  
251 independent cohorts onto our PCA space, PC scores maintained the original contrasts, confirming  
252 the good replicability of both PC signatures (one-sided sign test,  $P < 0.05$ ; **Supplementary Note;**  
253 **Extended Data Fig. 5c; Supplementary Table 9**). This PC-based approach successfully captured  
254 the continuous nature of SLE biology; most disease-activity PCs showed a gradual increase in the  
255 association signals along with the extent of disease activity (**Fig. 5b; Extended Data Fig. 7b**).

256 To overview cell-type-specific contributions to organ involvement, we first assessed the  
257 variance proportion of cell-type-specific PCs explained by clinical parameters (weighted variance  
258 partitioning analysis; **Methods**). Overall disease activity, a composite measure reflecting the status of  
259 all organs, significantly contributed to the within-SLE transcriptome variation especially in the 13 cell  
260 types including Th1, plasmablasts, and monocyte- and neutrophil-lineage cells (Bonferroni-corrected  
261 jackknife resampling  $P [P_{jk}] < 0.05$ ; **Fig. 2d; Fig. 5c, left; Methods**). We then decomposed the overall  
262 activity into seven organ/domain categories<sup>28,29</sup>: constitutional, mucocutaneous, musculoskeletal,  
263 renal, extrarenal severe, hematological, and serological activities (**Fig 5c, right; Extended Data Fig.**  
264 **8; Supplementary Table 10; Methods**). Interestingly, each organ/domain showed distinct cell-type-  
265 specific patterns. While Th1 showed the highest explained variance for mucocutaneous activity, the

Nakano M et al.

266 contribution of monocyte-lineage cells was predominant for musculoskeletal activity. Furthermore,  
267 neutrophil-lineage cells exhibited the largest contribution to renal involvement, followed by monocyte-  
268 lineage cells, Th1, and plasmablasts.

269 We next evaluated the specific relationship of each disease-activity PC with organ  
270 involvement (**Fig 5d; Supplementary Note; Supplementary Table 3**). For renal activity, neutrophil  
271 (Neu) PC1 and non-classical monocyte (NC Mono) PC2 showed strong associations (linear  
272 regression test; FDR < 0.05). We also identified significant associations of Naive CD4 PC7 and  
273 double negative (DN) B cell PC5 with musculoskeletal activity; these associations might be  
274 underestimated by the weighted variance partitioning analysis, which prioritizes the contribution of top  
275 PCs (**Methods**). Together, our results confirmed the critical roles of granulocytes and macrophages  
276 for the development of lupus nephritis (LN)<sup>48,49</sup>. In addition, our results also suggested other potential  
277 cell-type-specific contributions to organ involvement, which may be informative in unravelling SLE  
278 clinical heterogeneity.

279

### 280 **Cell-type-specific activity signatures linked to treatment responses.**

281 Belimumab (BLM) is a monoclonal antibody that inhibits BAFF, a vital factor for B cell survival and  
282 differentiation<sup>6,7,40</sup>. We investigated the effect of BLM on the transcriptome in each cell type (**Fig. 1,**  
283 **iv**). Our cohort has longitudinal data before and six months after BLM induction on 22 individuals; we  
284 refer to them as pre- and post-BLM. Importantly, none of the post-BLM samples were included in the  
285 discovery dataset; therefore, the comparison between pre- and post-BLM is independent of the



Nakano M et al.

286 disease-activity signatures calculated in the discovery dataset. We observed DEGs between pre- and  
287 post-BLM (BLM-DEGs) predominantly in B-lineage cells, confirming the cell-type-specific effects of  
288 BLM (**Fig. 6a**). When we categorized the patients into good and poor responders to BLM (n = 9 and  
289 13, respectively; **Methods**), more DEGs were observed in good than in poor responders (**Fig. 6b**;  
290 **Supplementary Data 4**). The IFN $\gamma$ -related, nuclear factor-kappa B (NF $\kappa$ B)-related, and glycolysis-  
291 related pathways were enriched in B cell DEGs of good responders (FDR < 0.05, one-sided Fisher's  
292 exact test; **Fig. 6c**; **Supplementary Table 11**), consistent with the downstream signaling of BAFF-  
293 receptors in B cells<sup>50,51</sup>.

294 We next asked whether BLM effects on transcriptomes counteract disease-activity  
295 signatures. We first calculated the Jaccard similarity index to quantify the shared genes between  
296 BLM-DEGs and disease-activity signatures; we considered a gene is shared when the BLM effect  
297 had the opposite sign to the activity signature to reflect therapeutic responses (**Method**). Jaccard  
298 indexes in good responders were around 3.4-fold higher than those in poor responders in B-lineage  
299 cells (**Fig. 6b**); the analyses based on logFC also showed similar trends. (**Supplementary Note**;  
300 **Extended Data Fig. 9a-b**). By projecting post-BLM data onto the PCA space of the discovery cohort  
301 (**Methods**), we evaluated the change in disease-activity PC scores between pre- and post-BLM.  
302 Consistent with the DEG analysis, we found a significant decrease in unswitched memory B cells  
303 (USM B) PC4 scores only for good responders (linear mixed regression test, FDR =  $9.9 \times 10^{-3}$ ; **Fig.**  
304 **6d**). Together, these results provided robust evidence supporting the association between disease-  
305 activity signatures and the therapeutic response to BLM.

Nakano M et al.

306           Next, we assessed the effect of other therapeutic agents such as mycophenolate mofetil  
307 (MMF) on disease-activity signatures (**Supplementary Data 5; Supplementary Fig. 2**). Importantly,  
308 we treated disease activity as a potential confounder in this analysis (**Methods**), and hence the MMF  
309 effects are not biased by disease activity. DEGs between patients with and without MMF (MMF-  
310 DEGs) were primarily observed in plasmablasts, followed by Th1 and central memory CD8+ T cells  
311 (CM CD8) (**Fig. 6e**); the same cell types were nominated by variance partitioning analysis (**Extended**  
312 **Data Fig. 9c; Supplementary Table 10**). MMF-DEGs were shared with the activity signature genes  
313 with 15.0-21.7% of the Jaccard index (**Fig. 6e**). Pathway analysis recapitulated this shared  
314 component: both genes showed enrichment for oxidative phosphorylation and E2F-related cell cycle  
315 pathways (**Extended Data Fig. 9d; Supplementary Table 12**). We also found a significant decrease  
316 in disease-activity PC scores of plasmablasts (PC1) in patients taking MMF, adjusted for disease  
317 activity (linear regression test,  $FDR = 6.3 \times 10^{-3}$ ; **Fig. 6f; Methods**). These results were consistent  
318 with previous reports that MMF suppressed plasma cell differentiation<sup>52,53</sup>.

319

### 320 **Risks variants for SLE are enriched around disease-state signatures, not activity signatures.**

321 To estimate the causal roles of these signatures for the risk of disease onset, we integrated our  
322 transcriptome data with the results of GWAS for SLE (SLE-GWAS; **Fig. 1, v**).

323           First, we analyzed the genome-wide distribution of all risk variants irrespective of their effect  
324 sizes and tested their enrichment around the signature genes using stratified linkage disequilibrium  
325 score regression<sup>26,54</sup> (S-LDSC; **Methods**). To be in line with previous studies of S-LDSC, we

Nakano M et al.

326 additionally took a conventional approach and analyzed the enrichment of specifically expressed  
327 genes (SEG) in each cell type derived from HC (HC-SEG; **Methods**). Since ancestry-specific GWAS  
328 results are required in S-LDSC, we used two large-scale SLE-GWAS conducted in East Asian  
329 (EAS)<sup>23</sup> and European (EUR)<sup>22</sup> populations. We confirmed that the S-LDSC results for EAS- and  
330 EUR-GWAS were globally similar as reported for other traits<sup>55</sup> ( $r$  in enrichment estimate = 0.69;  $P =$   
331  $1.5 \times 10^{-12}$ ; **Extended Data Fig. 10a; Supplementary Table 13**); hence we combined them using a  
332 fixed-effect meta-analysis. Consistent with previous reports<sup>26</sup>, the risk variants were predominantly  
333 enriched around HC-SEG of B-lineage cells but only with a nominal significance (minimum  $P = 0.028$   
334 for SM B): no significant enrichment at Bonferroni-corrected  $P < 0.05$  (**Fig. 7a**). Strikingly, compared  
335 to HC-SEG, we found much stronger enrichments for disease-state signatures in all cell types: nine  
336 significant enrichments. However, for disease-activity signatures, we found no significant enrichment.  
337 Consistently, the enrichments were substantially weaker in the activity signatures than in the disease-  
338 state signatures (paired Wilcoxon test,  $P = 5.5 \times 10^{-6}$ ).

339 We next analyzed candidate causal genes implicated in SLE-GWAS (**Methods**;  
340 **Supplementary Table 14**) and tested their enrichment in both signatures of each cell type (**Fig. 7b**;  
341 **Extended Data Fig. 10b; Supplementary Table 15**). As in the S-LDSC results, the enrichments of  
342 the candidate genes were predominantly observed in disease-state rather than in activity signatures;  
343 significant enrichments were found in five and zero cell types, respectively (Bonferroni-corrected  $P <$   
344  $0.05$ ). Again, the enrichments were weaker in activity signatures than disease-state signatures

Nakano M et al.

345 (paired Wilcoxon test,  $P = 2.5 \times 10^{-3}$ ). These results confirmed that the risk variants locate on average  
346 around disease-state and not activity signature genes.

347         Considering that most of the risk variants are within the gene regulatory regions<sup>25</sup>, we  
348 hypothesized that risk variants possess gene regulatory effects on disease-state genes (i.e., eQTL  
349 effects; **Fig. 7c**). To test this hypothesis, we next evaluated the potential eQTL effects of the risk  
350 variants on disease-state and activity signature genes. Specifically, we focused on genes affected by  
351 the risk variants' eQTL effects (eGenes) and asked how the risk alleles' directional effects on eGenes  
352 are consistent with our gene expression signatures; an eGene with consistent direction is called a  
353 "coherent gene"<sup>56</sup> (**Fig. 7d**; for this analysis, we utilized the colocalization test results between SLE-  
354 GWAS risk variants and eQTL variants that we recently reported<sup>27</sup>). Intriguingly, the coherent genes  
355 were enriched in disease-state signatures, but not in activity signatures (**Fig. 7e; Supplementary**  
356 **Table 16**): 67% of eGene-cell type combinations were coherent in disease-state signatures whereas  
357 only 25% of combinations were coherent in activity signatures (one-sided sign test,  $P = 0.022$  and  
358 0.99, respectively). Together, these analyses demonstrated better directional compatibility of the SLE  
359 risk allele's effect with disease-state signatures rather than activity signatures. Although this might be  
360 reasonable considering most GWAS are based on case-control design, this finding implied the failure  
361 of current GWAS to capture the critical biology of SLE represented by disease-activity signatures.

362         While activity signature genes did not locate around the current SLE risk variants, we  
363 speculated that some of them might contribute to the disease risk by modulating the eQTL effects of  
364 risk alleles (we refer to the genes with modulating eQTL effects as proxy genes [pGenes]<sup>57</sup>; **Fig. 7c**).

Nakano M et al.

365 Therefore, we finally sought to test whether disease-activity signature genes act as pGenes for risk  
366 alleles in SLE patients. We included 115 patients with available genotyping data and examined the  
367 influence of disease-activity signatures genes on the eQTL effects of risk alleles (we again utilized the  
368 abovementioned colocalization results<sup>27</sup>). Intriguingly, we detected two significant pGenes among  
369 activity signature genes (ANOVA test, FDR < 0.05; **Supplementary Data 6**), which included *MED24*,  
370 a transcriptional coactivator. *MED24* is an activity signature gene of plasmablasts (**Fig. 7f, left**), and  
371 its expression was suppressed by MMF (**Extended Data Fig. 10c**). *MED24* significantly modulated  
372 the eQTL effect of a SLE risk variant (rs36059542) on *ARHGAP31*, encoding a GTPase-activating  
373 protein (ANOVA test, FDR = 0.035; **Fig. 7f, right**). Of note, the eQTL effect of rs36059542 on  
374 *ARHGAP31* was observed only in plasmablasts<sup>27</sup>. Therefore, in addition to disease-state genes,  
375 disease-activity genes may also contribute to genetic risk by modulating the eQTL effects of risk  
376 alleles. Furthermore, MMF might indirectly suppress SLE genetic risk by controlling the *MED24*  
377 expression.

378

379 **Discussion**

380 In this study, we extensively examined dysregulated gene expression patterns of SLE by profiling 27  
381 immune cell types from 89 HC and 159 SLE donors. We identified two distinct categories of lupus-  
382 relevant signatures: disease-state and activity genes. These signatures revealed multiple novel and  
383 underappreciated mechanisms with a fine cellular resolution. Moreover, we demonstrated the value  
384 of these signatures in multiple applications: transferability to independent transcriptome datasets,  
385 shared components with drug responses and consistency with the genetic signals.

386 SLE is a chronic disease characterized by relapsing and remitting disease course<sup>1-3</sup>. A  
387 critical but unsolved question is how the multi-cellular pathophysiology is different (or not different)  
388 between disease development and exacerbation stages. Most of the previous SLE transcriptome  
389 studies have failed to provide clear answers since they separately conducted case-control and/or  
390 intra-case analyses and have not directly compared both signatures in the same study with a high  
391 cellular resolution. Our comprehensive transcriptome data successfully clarified the multiple cell-type-  
392 specific immune-mediated pathways characteristic of disease-state and activity, which highlighted the  
393 distinct biology behind the establishment and exacerbation phases of this disease.

394 The current realistic goal of SLE management is to achieve remission or low disease activity,  
395 not a cure<sup>58-60</sup>. From this perspective, the disease-activity signature, not the disease-state signature,  
396 has implications for development of biomarkers of treatment response or therapeutic targets. Indeed,  
397 we observed shared components between the disease-activity signatures and transcriptome changes  
398 in BLM good responders and in those taking MMF. The cell-type-specific activity signatures identified

Nakano M et al.

399 in this study, e.g., myeloid-lineage cells characteristic of renal disease, might be informative for  
400 designing novel treatment strategies for SLE.

401           We have provided in-depth integrative analyses of the risk variants and transcriptome  
402 signatures; these results have several important implications. First, since we recruited established  
403 SLE patients in the chronic phase, whether the disease-state signature genes indicate causality (the  
404 signatures induce disease-state) or a reverse-causality (the disease-state induces the signatures) is a  
405 critical question. Since the risk variants reflect the causality, the fact that the risk variants are  
406 enriched around disease-state signature genes suggested the former scenario, further supported by  
407 the consistency in the dysregulation direction (i.e., coherent genes). Moreover, this finding also  
408 suggested that genetic risk-driven susceptibility signatures remained in clinically stable SLE patients,  
409 indicating that the causal mechanism is not completely controlled by the current treatments. Second,  
410 the current GWAS signals failed to reflect the disease-activity signatures. This is a critical limitation of  
411 the current genetic studies considering the potential importance of activity signatures in drug target  
412 discovery. To resolve this issue, a new framework of genetic study focusing on intra-case  
413 heterogeneity (e.g., disease severity) will be required.

414           Although our study has substantially improved our understanding of SLE biology, we need to  
415 acknowledge several limitations. First, apart from the pre- and post-BLM sub-cohort, our study lacked  
416 longitudinal data. Second, all participants in this study were from the EAS population, although we  
417 demonstrated the applicability of our signatures to transcriptome data and GWAS results from

Nakano M et al.

418 multiple ancestries. Third, our cell-sorting strategy might have failed to characterize currently  
419 unidentified cell populations.


420 It is now clear that disease-state and activity signatures jointly maintain the complex  
421 pathophysiology of SLE. These signatures have the potential to be a pivotal foundation for future  
422 genomic, genetic, and drug discovery studies.

423




424

**Figures**




425 **Fig. 1| Overview of this study.** We profiled 6,386 RNA sequencing data of 27 immune cell types from peripheral blood in HC and  
426 SLE patients (**left**). We identified two distinct categories of disease-relevant signatures in a cell-type-specific manner (**middle**), and  
427 then performed extensive downstream analyses (**i-v**). BLM, belimumab; EAS, East Asian; EUR, European; TF, transcription factor.  
428

Nakano M et al.




429 **Fig. 2| Overview of gene expression patterns in the ImmNexUT cohort. a**, A heatmap showing the mean expression levels of  
 430 100 IRGs across all 27 cell types and diseases. Expression levels are scaled for each gene. Genes and clusters (G1-9) originate  
 431 from a PBMC scRNA-seq study<sup>20</sup>. Cell types are arranged consistently with the original publication where applicable. **b**, PCA plots  
 432 of HC and SLE gene expression data in representative cell types (see also **Extended Data Fig. 3**). **c**, A bar plot showing the  
 433 proportion of sum squared deviations within HC, SLE, and between HC and SLE data in each cell type. Cell types are arranged  
 434 based on the sum squared deviations within SLE. **d**, A bar plot showing the proportion of variance explained by the clinical  
 435 parameters within SLE data in each cell type. Cell types are arranged based on the variance explained by disease activity. In **a** and  
 436 **c-d**, column annotation colors indicate cell lineages. We used the discovery dataset (n=225) for all analyses in this figure. PSL,  
 437 prednisolone.  
 438




439 **Fig. 3| SLE disease-state and activity signatures.** **a, (left)** Scatter plots comparing the logFC of disease-state and activity  
 440 signature genes in representative cell types (see also **Extended Data Fig. 4a**). Colors indicate the significance of each signature.  
 441 **(right)** Box plots showing the expression of representative disease-state, activity and both significant signature genes. **b, Bar plots**  
 442 showing **(top)** the number of the union of disease-state/activity signature genes and **(bottom)** the proportion of DEG types in each  
 443 cell type. Cell types are separated into three groups (**Methods**). **c, Histograms** showing the proportion of the number of cell types  
 444 sharing DEG for both signatures. Colors indicate the number of shared cell lineages. **d, (left)** A heatmap showing the Jaccard  
 445 similarity indexes across all cell types in both signatures. The order of cell types in row and column are same and based on the  
 446 hierarchical clustering using the Jaccard indexes of disease-state signatures. **(right)** Box plots showing the expression of a  
 447 representative disease-activity signature gene shared by Th1, NK, and CD8+ memory T-lineage cells. Within each boxplot in **b** and  
 448 **d**, the horizontal lines reflect the median, the top and bottom of each box reflect the interquartile range (IQR), and the whiskers  
 449 reflect the maximum and minimum values within each grouping no further than 1.5 x IQR from the hinge. \*, DEG (FDR < 0.05);  
 450 N.S., not significant. We used the discovery dataset (n=225) for all analyses in this figure.

451




452 **Fig. 4| Cell-type-specific biology in disease establishment and exacerbation.** **a, (top)** Upregulated cytokines as disease-state  
 453 and/or activity signature genes for each cell type. Genes and cell types are hierarchically clustered based on differential expression  
 454 Z scores of activity signatures. **(bottom)** Boxplots showing the expression in representative cytokines. The horizontal lines reflect  
 455 the median, the top and bottom of each box reflect the IQR, and the whiskers reflect the maximum and minimum values within each  
 456 grouping no further than 1.5 x IQR from the hinge. \*, DEG (FDR < 0.05); N.S., not significant. **b, (top)** A bar plot showing the  
 457 number of significant TF annotation enrichments for each signature. **(middle)** A heatmap showing TF enrichment for each  
 458 signature. TFs and cell types are hierarchically clustered based on  $-\log_{10}(\text{enrichment } P)$  of activity signatures. Only the top three  
 459 TFs with strongest enrichments in each signature are shown, excluding redundant annotations. **(bottom)** Line graphs showing the  
 460 differential expression Z scores of 10 representative *BACH2* target genes in each cell type for both signatures. **c, Bar plots showing**  
 461 **(left)** the number of significant enrichments of metabolism- and cellular process-related pathways, and **(right)** the enrichment of  
 462 representative pathways for each signature. *P*, *P* values in one-sided Fisher's exact test. We used the discovery dataset (*n*=225)  
 463 for all analyses in this figure.

464




465 **Fig. 5| Cell-type-specific contribution to organ involvement in SLE.** **a**, Hierarchical clustering of 225 unique individuals based  
 466 on all PC1-7 scores of 27 cell types. Top annotations indicate the disease status and organ/domain activities in each individual.  
 467 Right annotations indicate the type and cell lineage of each PC. Here, only disease-state and/or activity PCs are shown in the  
 468 heatmap (see also **Extended Data Fig. 7a**). **b**, Box plots showing the scaled PC scores in representative disease-state, activity  
 469 and both significant PCs. The horizontal lines reflect the median, the top and bottom of each box reflect the IQR, and the whiskers  
 470 reflect the maximum and minimum values within each grouping no further than 1.5 x IQR from the hinge. \*, FDR < 0.05 in linear  
 471 regression test; N.S., not significant. **c**, Bar plots showing the proportion of variance explained by **(left)** the overall disease activity  
 472 and **(right)** representative organ/domain activities within SLE data in each cell type (see also **Extended Data Fig. 8**). Error bars  
 473 and dashed vertical lines indicate 95% confidence intervals from jackknife resampling and the median values across 27 cell types,  
 474 respectively. \*, Bonferroni-adjusted  $P_{jk} < 0.05$  (**Methods**). **d**, A heatmap showing the association of disease-activity PCs and  
 475 organ/domain activities in SLE.  $P$ , nominal  $P$  values; \*, FDR < 0.05 in linear regression test. We used the discovery dataset (n=225)  
 476 for all analyses in this figure.

477



478 **Fig. 6| Cell-type-specific activity signatures linked to treatment responses.** **a**, A bar plot showing the numbers of DEGs in  
 479 each cell type between all post- vs. pre-BLM patients (n=22 paired samples). **b**, Bar plots showing the numbers of BLM-DEGs and  
 480 Jaccard similarity indexes between BLM-DEGs and disease-activity signature genes in each cell type, separated into good (n=9)  
 481 and poor (n=13) responders. **c**, Bar plots showing the enrichment of representative pathways for the BLM-DEGs in B-lineage cells,  
 482 separated into good and poor responders. *P*, nominal *P* values; \*, FDR < 0.05 in one-sided Fisher's exact test. **d**, A box plot  
 483 showing the USM B PC 4 scores from pre- and post-BLM, separated into good and poor responders. *P*, nominal *P* values; \*, FDR <  
 484 0.05 in linear mixed regression test. **e**, Bar plots showing the numbers of DEGs between patients with (n=31) and without (n=105)  
 485 MMF (MMF-DEGs), and Jaccard indexes between MMF-DEGs and disease-activity signature genes in each cell type. **f**, A box plot  
 486 showing the plasmablasts PC 1 scores from patients with or without MMF. *P*, nominal *P* values; \*, FDR < 0.05 in linear regression  
 487 test. Within each boxplot in **d** and **f**, the horizontal lines reflect the median, the top and bottom of each box reflect the IQR, and the  
 488 whiskers reflect the maximum and minimum values within each grouping no further than 1.5 x IQR from the hinge. In **b** and **e**,  
 489 column annotation colors indicate cell lineages.


490



491 **Fig. 7 | Risks variants for SLE are enriched around disease-state signatures, not activity signatures.** **a**, Bar plots showing the  
 492 enrichment of SLE risk variants around HC-SEG, disease-state and activity signatures for each cell type. *P*, enrichment *P* values in  
 493 S-LDSC. Vertical dashed lines represent Bonferroni-significance. **b**, A scatter plot comparing the enrichment of SLE-GWAS  
 494 candidate genes in disease-state and activity signatures for each cell type. Only the cell types that pass Bonferroni-significance  
 495 (dashed lines) are annotated. *P*, *P* values in one-sided Fisher's exact test. **c**, Hypothesis of the association between the risk  
 496 variants and DEGs in SLE via eQTL effect. **d**, Box plots showing the expression patterns in representative coherent and incoherent  
 497 genes. *P*, *P* values in linear regression (left) and differential expression test (right). **e**, Histogram of adjusted logFC in coherent and  
 498 incoherent genes for disease-state and activity signatures. *P*, *P* values in one-sided sign test. **f**, Box plots showing (**left**) the  
 499 differential expression of *MED24*, an activity signature gene in plasmablasts and (**right**) the influence of *MED24* on the eQTL effect  
 500 of a SLE risk variant rs36059542 on *ARHGAP31*. *P*, *P* values in differential expression (left) and ANOVA test (right). Within each  
 501 boxplot in **d** and **f**, the horizontal lines reflect the median, the top and bottom of each box reflect the IQR, and the whiskers reflect  
 502 the maximum and minimum values within each grouping no further than 1.5 x IQR from the hinge. We used the discovery dataset  
 503 (n=225) for all analyses in this figure.


504

505 **Extended Data Figures**




506 **Extended Data Fig. 1| Overview of gene expression patterns in the ImmuneNexUT cohort.** **a**, Bar plots showing the number of  
 507 samples that passed quality control (QC, **Methods**) in each cell type. **b**, A PCA and **c**, a UMAP plot of all samples. Colors and  
 508 shapes indicate cell types and diseases, respectively. We used all 6,386 samples from 248 donors for all analyses in this figure.  
 509







510 **Extended Data Fig. 2| Batch correction procedure in this study.** **a**, PCA plots of HC and all SLE gene expression data in each  
 511 cell type (**top**) before and (**bottom**) after batch correction. Colors and shapes represent each batch and disease, respectively. **b**,  
 512 Bar plots showing the proportion of variance explained by batch effect and disease in the gene expression data for each cell type  
 513 (**left**) before and (**right**) after batch correction. We used all 6,386 samples from 248 donors for all analyses in this figure.  
 514




515 **Extended Data Fig. 3| Overview of gene expression patterns in the ImmNexUT cohort.** PCA plots of HC and unique SLE  
 516 gene expression data in each cell type. We used the discovery dataset (n=225) for this analysis.  
 517




518 **Extended Data Fig. 4| SLE disease-state and activity signatures.** **a**, Scatter plots comparing the logFC of disease-state and  
 519 activity signature genes in all cell types. Each dot represents one gene, colored based on the significance (FDR < 0.05 in  
 520 differential expression test) of each comparison. Genes with logFC > 5 are plotted at the position of logFC = 5. **b**, A barplot showing  
 521 the numbers of disease-state and activity signature genes in each cell type. **c**, A barplot showing the Spearman correlations  
 522 between the logFC in disease-state and activity signatures for each cell type. In **b** and **c**, cell types are separated into three groups  
 523 (**Methods**). **d**, A heatmap showing the Spearman correlations across all cell types in disease-state and activity signatures. The  
 524 order of cell types in row and column are same and based on the hierarchical clustering using the Spearman correlation  
 525 coefficients of disease-activity signatures. In **b** and **d**, row and column annotation colors indicate cell lineages. We used the  
 526 discovery dataset (n=225) for all analyses in this figure.  
 527



528 **Extended Data Fig. 5| Lupus disease-state and activity signatures are replicable in independent cohorts. a, (top)** Heatmaps  
 529 showing the concordance between the disease-state signatures in the current study (HC, n=89; inactive SLE, n=31) and those in  
 530 replication cohort 1 (left heatmap; HC, n=24; inactive SLE, n=16) and 2 (right heatmap; HC, n=37; inactive SLE, n=10). **(bottom)**  
 531 Scatter plots comparing disease-state effects (logFC) of the current study and those of replication cohort 1 (left panel) and 2 (right  
 532 panel) in representative corresponding (left plot in blue frame) and non-corresponding (right plot in black frame) cell-type  
 533 combinations. **b, (top)** Heatmaps showing the concordance between the disease-activity signatures in the current study (inactive,  
 534 n=31; HDA SLE, n=30) and those in replication cohort 1 (left heatmap; inactive, n=16; HDA SLE, n=6) and 3 (right heatmap;  
 535 inactive, n=41; HDA SLE, n=4). **(bottom)** Scatter plots comparing disease-activity effects (logFC) of the current study and those of  
 536 replication cohort 1 (left panel) and 3 (right panel) in representative corresponding (left plot in red frame) and non-corresponding  
 537 (right plot in black frame) cell-type combinations. *P*, *P* values in one-sided sign test. In all heatmaps, only the combinations that  
 538 pass Bonferroni-significance are colored. In scatter plots, each dot represents one signature gene. Genes with logFC > 5 in either  
 539 comparison are plotted at the position of logFC = 5. **c, (top)** Scatter plots comparing the effect sizes of disease-state PCs in the  
 540 current study and those in replication cohorts (cohort 1 and 2). The PCs with nominal *P* < 0.05 in linear regression test in replication  
 541 cohorts are colored. **(bottom)** Scatter plots comparing the effect sizes of disease-activity PCs in the current study and those in  
 542 replication cohorts (cohort 1 and 3). The PCs with nominal *P* < 0.05 in linear regression test in replication cohorts are colored.  
 543




544 **Extended Data Fig. 6| Cell-type-specific biology in disease establishment and exacerbation. a,** Bar plots showing the number  
 545 of significant (**left**) MsigDB HALLMARK and (**right**) KEGG pathway enrichments for disease-state and activity signature genes in  
 546 each cell type. **b,** Bar plots showing the enrichment of representative MsigDB HALLMARK pathways for each signature. **c,**  
 547 Classification of 774 KEGG pathway annotations significantly enriched in any signatures (FDR < 0.05 in one-sided Fisher's exact  
 548 test) into four main categories and 33 subcategories (**Methods**). We used the discovery dataset (n=225) for all analyses in this  
 549 figure.  
 550




551 **Extended Data Fig. 7 | Disease-state and activity PCs in the discovery dataset. a,** Hierarchical clustering of 225 unique  
 552 individuals based on all PC1-7 scores of 27 cell types. Top annotations indicate the disease status and organ/domain activities in  
 553 each individual. Right annotations indicate the type and cell lineage of each PC. **b,** A heatmap showing the association of PC  
 554 scores with disease-state/activity in linear regression test. All PCs with significant association with disease-state and/or disease-  
 555 activity are shown (\*, FDR < 0.05). We used the discovery dataset (n=225) for all analyses in this figure.

556




557 **Extended Data Fig. 8| Cell-type-specific contribution to organ involvement in SLE.** Bar plots showing the proportion of  
 558 variance explained by organ/domain activities within SLE data in each cell type. Here, the results for the four organ/domain  
 559 activities other than those in **Fig. 5c, right** are shown. Error bars and dashed vertical lines indicate 95% confidence intervals from  
 560 jackknife resampling and the median values across 27 cell types, respectively. \*, Bonferroni-adjusted  $P_{jk} < 0.05$  (**Methods**). We  
 561 used SLE patients in the discovery dataset (n=136) for this analysis.  
 562



563 **Extended Data Fig. 9 | Cell-type-specific activity signatures linked to treatment responses.** **a**, Scatter plots comparing the  
 564 disease-activity effects (logFC) and BLM effects (logFC) of the activity signature genes in each cell type, separated into good and  
 565 poor responders. Each dot represents one gene. Genes with logFC > 5 are plotted at the position of logFC = 5. **b**, Bar plots  
 566 showing the effect sizes in the linear regression tests for the association between disease-activity effects and BLM effects,  
 567 separated into good and poor responders. **c**, Bar plots showing the proportion of variance explained by medication status of MMF  
 568 within SLE data in each cell type. Error bars and dashed vertical lines indicate 95% confidence intervals from jackknife resampling  
 569 and the median values across 27 cell types, respectively. \*, Bonferroni-adjusted  $P_{jk} < 0.05$  (**Methods**). **d**, Bar plots showing the  
 570 enrichment of representative pathways for the MMF-DEGs in Th1, CM CD8, and plasmablast.  $P$ , nominal  $P$  values; \*, FDR < 0.05  
 571 in one-sided Fisher's exact test. For BLM-related analyses, we used the pre- ( $n=22$ ) and post-BLM ( $n=22$ ) patients. For MMF-  
 572 related analyses, we used the patients with ( $n=31$ ) and without ( $n=105$ ) MMF.  
 573





574 **Extended Data Fig. 10| Risks variants for SLE are enriched around disease-state signatures, not activity signatures. a,**  
 575 Scatter plots comparing the normalized coefficients in S-LDSC for EAS and EUR SLE-GWAS. Each dot represents each signature  
 576 (i.e., [HC-SEGs, disease-state and disease-activity signatures] × 27 cell types). The signatures that pass Bonferroni-significance in  
 577 meta-analysis are annotated. **b,** A bar plot showing the direct comparison of GWAS candidate genes enrichment between disease-  
 578 state and activity signature genes for each cell type using one-sided Fisher's exact test. Dashed horizontal line indicates odds ratio  
 579 (OR) = 1. \*; nominal  $P < 0.05$ . **c,** A Box plot showing the expression of *MED24* in plasmablasts between patients with and without  
 580 MMF.  $P$ ,  $P$  values in differential expression test. Within each boxplot, the horizontal lines reflect the median, the top and bottom of  
 581 each box reflect the IQR, and the whiskers reflect the maximum and minimum values within each grouping no further than 1.5 x  
 582 IQR from the hinge. We used the discovery dataset (n=225) for all analyses in this figure.  
 583

584 **Methods**

585 **Subjects**

586 The data in our study was generated by the ImmuNexUT consortium<sup>27</sup>, approved by the Ethics  
587 Committees of the University of Tokyo. All participants were from the EAS ancestry. Healthy  
588 volunteers were recruited at the Department of Allergy and Rheumatology at the University of Tokyo  
589 Hospital. SLE patients were recruited at the Department of Allergy and Rheumatology at the  
590 University of Tokyo Hospital, Division of Rheumatic Diseases at National Center for Global Health  
591 and Medicine, or Immuno-Rheumatology Center at St. Luke's International Hospital. Written informed  
592 consent was obtained from all participants. We have complied with all of the relevant ethical  
593 regulations.

594 All SLE patients met the 1997 revised version of the American College of Rheumatology  
595 classification criteria<sup>61</sup>. The exclusion criteria for the discovery dataset (including 136 SLE patients)  
596 were: i) active malignancies or infections, ii) use of more than 20mg prednisolone (PSL) daily or  
597 equivalent at enrollment, iii) receive of intravenous methylprednisolone pulse, cyclophosphamide,  
598 rituximab, or BLM within 12 months before enrollment.

599 In addition, we also collected 22 paired samples just before and six months after the  
600 additional therapy of BLM (i.e., pre- and post-BLM). Among the pre-BLM samples, 21 samples were  
601 included in the discovery dataset, and one was re-sampled due to the interval between initial  
602 enrollment and BLM induction. None of the post-BLM samples were included in the discovery

603 dataset. Therefore, we recruited 248 donors in total: 136 unique SLE patients, one pre-BLM, 22 post-  
604 BLM patients, and 89 healthy volunteers.

605

## 606 **Sample processing and sequencing**

607 In this study, all samples were collected based on phase 2 protocol in the ImmuNexUT<sup>27</sup>; 27 immune  
608 cell types were purified from peripheral blood of each donor (**Supplementary Table 1**). We first  
609 isolated PBMCs by density gradient separation with Ficoll-Paque (GE healthcare) immediately after  
610 the blood draw. Erythrocytes were lysed with Ammonium-Chloride-Potassium lysing buffer (Gibco),  
611 and non-specific binding was blocked with anti-human Fc-gamma receptor antibodies (Thermo Fisher  
612 Scientific). We next sorted PBMCs into 26 immune cell types with purity > 99% using a 14-color cell  
613 sorter BD FACSAria Fusion (BD Biosciences) with the aim of 5,000 cells per sample. The immune  
614 cell gating strategy for flow cytometry was based on the Human Immunology Project with slight  
615 modification<sup>62</sup>. Sorted cells were lysed and stored at -80°C. RNA was extracted using MagMAX-96  
616 Total RNA Isolation Kits (Thermo Fisher Scientific). Libraries for RNA-seq were prepared using  
617 SMART-seq v4 Ultra Low Input RNA Kit (Takara Bio). Neutrophils were purified using MACSxpress  
618 Neutrophil Isolation Kits human (Miltenyi Biotec) with the aim of  $2 \times 10^6$  cells immediately after the  
619 blood draw, lysed and stored at -80°C, followed by RNA isolation with an RNeasy Mini Kits (QIAGEN)  
620 and library preparation with SMART-seq v4 Ultra Low Input RNA Kits (Takara Bio). All prepared  
621 libraries were sequenced on HiSeq2500 (6169 samples) or NovaSeq6000 (217 samples) (Illumina) to  
622 generate 100 or 150 base paired-end reads, respectively. Genomic DNA was isolated from peripheral

623 blood using QIAmp DNA Blood Midi kit (QIAGEN). Libraries were prepared using TruSeq DNA PCR-  
624 Free Library prep kit (Illumina), followed by whole-genome sequencing (WGS). WGS was performed  
625 only for the samples from Japanese individuals. The details of WGS data processing were reported in  
626 our previous study<sup>27</sup>.

627

628 **Quantification and normalization of the expression data**

629 Adaptor sequences were trimmed using Cutadapt (v1.16) and reads containing low-quality bases  
630 (Phred quality score < 20 in > 20% of the bases) were removed. Reads were aligned against the  
631 GRCh38 reference sequence using STAR<sup>63</sup> (v2.5.3) with the UCSC (downloaded from illumina  
632 iGenome reference collection, archive-2015-08-14-08-18-15) and expression was counted with  
633 HTSeq<sup>64</sup>.

634 We applied multiple sample quality control (QC) steps to ensure high quality data. The  
635 samples with uniquely mapped read rates < 80% or unique read counts <  $5 \times 10^6$  were excluded as  
636 low-quality samples. To exclude outlier samples, we calculated Spearman's correlations of the  
637 expressions between two samples from the same cell type and then removed the samples with mean  
638 correlation coefficients < 0.9. In addition, to exclude potentially swapped samples, we calculated the  
639 concordance rates between RNA-seq-based genotype and WGS-based genotype at the  
640 heterozygous loci and excluded samples with concordance rate < 0.9.

641 We then filtered out low expression genes (<10 counts or <1 count per million [CPM] in >  
642 85% of samples), followed by a trimmed mean of M values (TMM) normalization with R (v4.0.2)

643 package edgeR (v3.32.1)<sup>65</sup> in each cell type. Normalized expression data were converted to log-  
644 transformed count per million (i.e.,  $\log[\text{CPM}+1]$ ). The batch effects (i.e., product lots in SMART-seq  
645 v4 and sequencer; **Extended Data Fig. 2a**) were removed using Combat software<sup>66</sup>. To verify the  
646 successful work of the batch correction procedure, we used principal variance component analysis;  
647 we first calculated the explained variance of each clinical parameter for each PC1-7 score with the  
648 linear mixed models in R package lme4 (v1.1-27.1)<sup>67</sup> and then inferred the average value of the  
649 explained variance weighted by each PC's eigenvalue (**Extended Data Fig. 2b**).

650

#### 651 **PCA and UMAP of all samples**

652 For PCA and UMAP using all samples (**Extended Data Fig. 1b-c**), we combined the expression data  
653 after batch correction from each cell type and used the intersection of the genes (n=8397) that  
654 passed the filtering of low expression in each cell type. For UMAP, we used R package uwot (v  
655 0.1.10) with default parameters<sup>68</sup>.

656

#### 657 **PCA in each cell type of the discovery dataset**

658 For PCA in each cell type of the discovery cohort, we used the top 10,000 variable genes from the  
659 expression data after batch correction in each cell type (**Fig. 2b; Extended Data Fig. 3**).

660 To calculate the proportion of sum squared deviations within HC, SLE, and between HC and  
661 SLE data in each cell type (**Fig. 2c**), we used the PC1-7 data of the discovery dataset

662 **(Supplementary Note)**. We first calculated the proportion of sum squared deviations for each PC  
663 score and then inferred the average value of the proportion weighted by each PC's eigenvalue.

664  
665 **Weighted variance partitioning analysis in each cell type**

666 To calculate the explained variance of each clinical parameter within SLE transcriptome data for each  
667 cell type, we performed weighted variance partitioning analysis using the PC1-7 data of the discovery  
668 dataset **(Supplementary Note)**. We first calculated the explained variance of each clinical parameter  
669 for each PC score using the linear mixed models in R package variancePartition (v1.20.0)<sup>69</sup> and then  
670 inferred the average value of the explained variance weighted by each PC's eigenvalue **(Fig. 2d, 5c;**  
671 **Extended Data Fig. 8, 9c; Supplementary Fig. 2b)**.

672 To verify whether the inferred explained variance was not biased by outlier samples, we  
673 estimated standard errors (S.E.) of the explained variance by jackknife resampling method. When we  
674 had  $n$  samples for one cell type, we re-calculated the explained variance  $n$  times by excluding each  
675 one of the samples. We then evaluated the distribution of  $n$  explained variance and quantified its S.E.  
676 For each clinical parameter, we compared the explained variance in each cell type against the  
677 median explained variance across all 27 cell types. To assess the significance of the difference  
678 observed in this comparison for a cell type, we utilized  $n$  explained variance calculated in jackknife  
679 resampling for that cell type; among  $n$  values, we calculated the proportion of the values which was  
680 smaller than the median value, and we defined this proportion as jackknife resampling  $P$  ( $P_{jk}$ ). For  
681 each clinical parameter, if one cell type passed the Bonferroni-corrected  $P_{jk} < 0.05$ , we concluded that

682 the clinical parameter significantly contributed to the within-SLE transcriptome variation in that cell  
 683 type.

684

### 685 **Linear models for the association between PC scores and clinical parameters**

686 This study focused on the clinical parameters related to disease-state, overall disease-activity,  
 687 organ/domain activity, and treatment statuses (**Supplementary Fig. 1a**). Disease-state was defined  
 688 as the contrast between inactive SLE (i.e., not all SLE) and HC in the discovery dataset to exclude  
 689 the elements of disease-activity signatures from the case-control contrast (**Fig. 1, middle**). For  
 690 overall disease activity, we defined four categories: i) inactive as SLEDAI-2K<sup>28</sup> = 0, ii) low disease  
 691 activity (LDA) as  $1 \leq \text{SLEDAI-2K} \leq 4$ , iii) moderate disease activity (MDA) as  $5 \leq \text{SLEDAI-2K} \leq 8$ , and  
 692 iv) high disease activity (HDA) as  $\text{SLEDAI-2K} \geq 9$ . For organ activity, we categorized the patients into  
 693 seven groups based on their actively involved organ/domains of the British Isles Lupus Assessment  
 694 Group (BILAG) 2004<sup>29</sup> and SELDAI-2K: a) constitutional, b) mucocutaneous, c) musculoskeletal, d)  
 695 renal, e) extrarenal severe (neuropsychiatric/eye, cardiorespiratory and/or gastrointestinal), f)  
 696 hematological, and g) serological activities. We also evaluated the effect of therapeutic agents such  
 697 as MMF, hydroxychloroquine (HCQ), and tacrolimus (TAC)<sup>3,60,70</sup>.

698 To examine the associations between the PC scores (PC1-30) and clinical traits, we fitted  
 699 the PC scores to the following linear regression models:

700 (1) For disease-state ( $x$ : inactive SLE vs. HC),

$$701 \quad y = \beta \cdot x[0,1] + \varepsilon \cdot \text{Age}[\text{yrs}] + \epsilon \cdot \text{Sex}[0,1] + \theta$$

702 Here,  $y$  represents the scaled PC score for each cell type (PC1-30 × 27 cell types). All PC scores  
 703 were scaled across samples to enable the direct comparison of the effect sizes in the associations  
 704 with clinical parameters. In this comparison, age and sex were included as covariates.

705 (2) For disease-activity ( $x$ : HDA vs. inactive SLE; we also examined LDA vs. inactive and MDA vs.  
 706 inactive SLE),

$$707 \quad y = \beta \cdot x[0,1] + \sum_{k=1,2,3} \gamma \cdot I_k[0,1] + \delta \cdot PSL[mg] + \varepsilon \cdot Age[yrs] + \epsilon \cdot Sex[0,1] + \theta$$

708 Here,  $I_k$  ( $k = 1,2,3$ ) represents each immunosuppressant (MMF, HCQ, TAC) as covariates.

709 (3) For organ/domain activity ( $x_j$  [ $j = 1 \dots 7$ ]: the abovementioned seven categories),

$$710 \quad y = \sum_{j=1\dots7} \beta \cdot x_j[0,1] + \sum_{k=1,2,3} \gamma \cdot I_k[0,1] + \delta \cdot PSL[mg] + \varepsilon \cdot Age[yrs] + \epsilon \cdot Sex[0,1] + \theta$$

711 Here, we constructed multiple linear regression models including all seven categories, which enabled  
 712 us to infer the association of each organ activity with PC scores, controlling the other organs' effects

713 **(Fig. 5c-d).**

714 (4) For therapeutic agents ( $I_k$  [ $k = 1,2,3$ ]: MMF, HCQ, TAC),

$$715 \quad y = \sum_{k=1,2,3} \gamma \cdot I_k[0,1] + \beta \cdot x[0,1,2,3] + \delta \cdot PSL[mg] + \varepsilon \cdot Age[yrs] + \epsilon \cdot Sex[0,1] + \theta$$

716 Here,  $x$  represents disease activity (inactive, LDA, MDA, and HDA) as covariates.

717 These equations enabled us to derive the associations of disease-state, activity, organ

718 involvements or treatment statuses with PC scores, adjusted for other confounding factors. Statistical  
 719 significance was set at  $FDR < 0.05$ . As described in **Supplementary Note** and **Supplementary Fig.**

720 **1b**, most of the significant associations were detected within PC1-7, with larger numbers than

721 average per PCs. Therefore, we confirmed that PC1-7 is a minimum set to associate the



722 transcriptome with the clinical parameters in the discovery dataset and utilized PC1-7 scores for the  
723 subsequent analyses. All PC scores were signed so that the effect sizes of disease-state and  
724 disease-activity were positive (**Fig. 5a-b; Extended Data Fig. 7a-b**). In the case of some PCs that  
725 had opposite sign in the effect sizes of disease-state and activity, the association with lower *P* value  
726 was prioritized to have positive effect size.

727           In the hierarchical clustering of 225 unique individuals using 189 PCs (= 7 PCs × 27 cell  
728 types) in the discovery dataset, the Euclidean distances of the PC scores were used with Ward's  
729 method (**Fig. 5a; Extended Data Fig. 7a**).

730

### 731 **Differential gene expression analysis**

732 To detect DEGs in each cell type, we fitted the TMM-normalized counts in the discovery dataset to  
733 the generalized linear models (GLM) with negative binomial distribution using edgeR (v3.32.1)<sup>65</sup>. The  
734 equations in these GLM models were consistent with those in the linear models as described in the

735 **Methods; Linear models for the association between PC scores and clinical parameters**; we  
736 utilized the equations (1), (2) and (4). Additionally, we also considered the batch effects as covariates  
737 in this analysis since TMM-normalized counts were not corrected for batch effects (**Methods;**

738 **Quantification and normalization of the expression data**). These equations enabled us to derive  
739 DEGs related to our focused disease traits or treatment statuses, adjusted for other confounding  
740 factors (**Fig. 3a-b, 6e; Supplementary Fig. 2a**). Statistical significance was set at FDR < 0.05. We  
741 defined (1) “disease-state signature genes” as significant DEGs between inactive SLE and HC, and

742 (2) “disease-activity signature genes” as significant DEGs between HDA and inactive SLE for each  
743 cell type (**Fig. 3a**).

744 To evaluate the similarities and differences between disease-state and activity signature  
745 genes, we calculated Jaccard similarity indexes as the ratio of the shared genes with the concordant  
746 sign between the disease-state and activity signatures (**Fig. 3a**; orange dots) over the union of these  
747 two signature genes (**Fig. 3a**; orange + red + blue dots) for each cell type. Considering the biological  
748 significance, we did not regard the DEGs with the discordant sign between these two signatures as  
749 shared genes. Based on the proportion of DEGs and Jaccard index, we classified 27 cell types into  
750 three patterns (**Fig. 3b**). We first defined the cell types with Jaccard index  $> 0.15$  as shared pattern  
751 and then classified the other cell types into disease-state or disease-activity dominant patterns based  
752 on which signature genes were numerically predominant.

753 We also calculated the Jaccard similarity index and Spearman correlation across all pairs of  
754 different cell types for both signature genes. The Jaccard similarity distances (i.e.,  $1 - \text{Jaccard}$   
755 similarity indexes) of each pair within disease-state signature genes were used for hierarchical  
756 clustering (**Fig. 3d**). Similarly, Spearman’s correlation distance of each pair within disease-activity  
757 signature genes were used for hierarchical clustering (**Extended Data Fig. 4d**).

758 To detect DEGs related to therapeutic agents adjusted for confounding factors (e.g., disease  
759 activity), we set the patients not taking the agent as the control, meaning the down-DEGs  
760 represented the genes that were downregulated by each agent. Therefore, we calculated Jaccard  
761 indexes as the ratio of the shared genes with the inverse sign between the disease-activity signatures

762 and MMF-DEGs over the union of these two signature genes (**Fig. 6e**). We calculated Jaccard  
763 indexes within the cell types in which more than 300 MMF-DEGs were observed.

764

## 765 **Replication analysis**

766 For replication analysis, we compared our data with the three external bulk immune cell RNA-seq  
767 dataset of SLE and/or HC from different ancestries.

### 768 i) Cohort 1 (Panwar *et al.*<sup>33</sup>)

- 769 • Samples: 64 SLE and 24 HC, multi-ancestry cohort (Caucasian, Asian, Hispanic, and African)
- 770 • Cell subsets: six cell types (bulk T cells, bulk B cells, CL Mono, mDC, pDC, and Neu). Only  
771 CL Mono was collected from all donors, and the other five cell types were collected from  
772 around 20 SLE and 10 HC samples.
- 773 • Data usage strategy: since this cohort included both SLE and HC, we used this cohort for the  
774 replication analysis of disease-state and activity signatures (**Extended Data Fig. 5a-c**). Naive  
775 CD4 and naive B data from the current study were compared with bulk T and bulk B data from  
776 cohort 1, respectively (**Supplementary Table 4**).

### 777 ii) Cohort 2 (Takeshima *et al.*<sup>35</sup>)

- 778 • Samples: 30 SLE and 37 HC, All East Asian (EAS)
- 779 • Cell subsets: 19 cell types (Naive CD4, Mem CD4, Th1, Th2, Th17, Tfh, Fr. II eTreg, Naive  
780 CD8, bulk memory CD8 [Mem CD8], NK, Naive B, USM B, SM B, DN B, plasmablast, CL  
781 Mono, CD16p Mono, mDC, and pDC)

782 • Data usage strategy: this is our previous cohort independent of the ImmuNexUT. In this  
783 study, we excluded the overlapped samples with the current study, leaving relatively stable  
784 30 SLE patients for the analysis. Therefore, we used this cohort only for the replication of  
785 disease-state signatures (**Extended Data Fig. 5a, c**). EM CD8 data from the current study  
786 was compared with bulk Mem CD8 data from cohort 2 (**Supplementary Table 4**).

787 iii) Cohort 3 (Andreoletti *et al.*<sup>34</sup>)

- 788 • Samples: 57 White and 63 Asian SLE patients
- 789 • Cell subsets: four cell types (bulk CD4 cells, NK cells, bulk B cells, and bulk monocytes)
- 790 • Data usage strategy: since this cohort did not include HC samples, we used this cohort only  
791 for the replication of disease-activity signatures (**Extended Data Fig. 5b-c**). Naive CD4, naive  
792 B, and CL Mono data from the current study were compared with bulk CD4, bulk B, and bulk  
793 monocyte data from cohort 3, respectively (**Supplementary Table 4**).

794 In all replications, we assessed the concordance of the directions of disease-state and  
795 activity signature genes in the discovery cohort with the corresponding genes in external cohorts  
796 using one-sided binomial sign tests (**Extended Data Fig. 5a-b**). The definitions of clinical status (e.g.,  
797 disease-state and activity) were consistent with our discovery cohort, with the exception that inactive  
798 SLE in cohort 2 was defined as  $0 \leq \text{SLEDAI-2K} \leq 2$  (10 patients) since there were no patients with  
799 SLEDAI-2K = 0. In all replication analyses, we adjusted for the covariates (e.g., age and sex) in line  
800 with the analyses of the discovery dataset where applicable.

801 In the PC projection method, we first computed the Z score matrix of gene expressions using  
802 the mean and standard deviation (SD) of the discovery dataset and then inferred the PC scores of  
803 each sample from the external datasets as the inner products of each PC loading (**Supplementary**  
804 **Data 1**) and the Z score matrix. We tested the association of these PC scores with disease-state (i.e.,  
805 inactive SLE vs. HC) and disease-activity (i.e., HDA vs. inactive SLE) in the external datasets using  
806 the linear regression model as with the discovery dataset (**Supplementary Table 9**). We then  
807 assessed the concordance of the directions of the effect sizes for disease-state and disease-activity  
808 PCs, respectively, using one-sided binomial sign tests (**Supplementary Note; Extended Data Fig.**  
809 **5c**).

810

### 811 **Transcription factor and pathway enrichment analysis**

812 To test pathway and transcription factor (TF) enrichment in each disease-state and activity signature  
813 genes, we performed over-representation analyses with one-sided Fisher's exact test in R package  
814 clusterProfiler (v.3.18.1)<sup>71</sup>. Statistical significance was set at FDR < 0.05. For TF datasets, we used  
815 the Molecular Signatures Database (MsigDB) C3 all TF targets annotation (1133 annotations)<sup>72</sup>. For  
816 pathway datasets, we used the MsigDB hallmark gene set collection (50 annotations)<sup>73</sup> and Kyoto  
817 Encyclopedia of Genes and Genomes (KEGG) pathway (548 annotations)<sup>74</sup>. To capture the cell-type-  
818 specific biology linked to disease-state and activity signatures genes, we set the union of both  
819 signature genes in all cell types as the background gene sets. For treatment-related DEGs (e.g.,

820 MMF-DEGs and BLM-DEGs), we performed pathway enrichment analysis only in the cell types in  
 821 which more than 300 DEGs were observed.

822

### 823 **Analysis of pre- and post-BLM dataset**

824 All 22 individuals received BLM treatment according to the standard protocols<sup>6,7,75</sup>. In this section, we  
 825 defined those whose original disease-activity categories were moved into one or more lower  
 826 categories (e.g., MDA to LDA or LDA to inactive) between pre- and post-BLM treatment, as good  
 827 responders, and the others as poor responders.

828 Because edgeR did not implement generalized linear mixed models (GLMM), we detected  
 829 DEGs between pre- and post-BLM using the following GLMM with negative binomial distribution in  
 830 lme4 (v1.1-27.1)<sup>67</sup>, setting the statistical significance at FDR < 0.05 (**Fig. 6a-b**). Of note, we need to  
 831 consider the batch effects as covariates in the following equation, since TMM-normalized counts were  
 832 not corrected for batch effects (**Methods; Quantification and normalization of the expression**  
 833 **data**).

$$834 \quad y = \beta \cdot BLM[0,1] + (1|individual) + \pi \cdot Batch + \theta$$

835 Here,  $y$  and  $BLM$  represents the TMM-normalized count for each gene in each cell type  
 836 and the treatment status of BLM (i.e., pre- and post-BLM). We included a term for random intercept of  
 837 individuals, and hence excluded individual-specific covariates (e.g., age and sex). In this equation, we  
 838 set pre-BLM as the control, meaning the down-DEGs represented the genes that were  
 839 downregulated by BLM treatment. Therefore, we calculated Jaccard indexes as the ratio of the

840 shared genes with the inverse sign between the disease-activity signatures and BLM-related DEGs  
 841 over the union of these two signature genes (**Fig. 6b**). We calculated Jaccard indexes within the cell  
 842 types in which more than 300 BLM-DEGs were observed. Moreover, in each cell type, we compared  
 843 associations between the logFC of disease-activity effect and those in BLM effect using linear  
 844 regression model (**Supplementary Note; Extended Data Fig. 9a-b**).

845 In the PC projection method, we first computed the Z score matrix of gene expressions using  
 846 the mean and SD of the discovery dataset and then inferred the PC scores of duplicated samples as  
 847 the inner products of each PC loading (**Supplementary Data 1**) and the Z score matrix. To test the  
 848 association between the change of PC scores and the treatment status, we used the following linear  
 849 mixed model:

$$850 \quad y = \beta \cdot BLM[0,1] + (1|individual) + \theta$$

851 Here,  $y$  represents the scaled PC score for each cell type. In this model, it was not necessary to  
 852 consider the batch effects since the PCA was performed using the log(CPM+1) gene expression data  
 853 that had been already corrected for batch effects (**Methods; Quantification and normalization of**  
 854 **the expression data**).

### 855

### 856 **Stratified linkage disequilibrium score regression**

857 To evaluate the enrichment of the genome-wide distribution of all SLE risk variants irrespective of  
 858 their effect sizes (heritability) around HC-SEG, disease-state and activity signature genes, we  
 859 performed S-LDSC<sup>26,54</sup>. We examined the enrichment of SLE heritability for common variants within

860 100-kb windows on either side of the transcription start site of the genes with the top 1,000 highest Z-  
861 scores in either signature genes for each cell type, adjusting for baseline model provided by the  
862 developers<sup>54</sup> (**Fig. 7a**). For this analysis, we used two large-scale SLE GWAS summary statistics  
863 from EAS<sup>23</sup> and EUR ancestries<sup>22</sup> (**Extended Data Fig. 10a**). Since the regression coefficients of S-  
864 LDSC are influenced by the GWAS heritability, we normalized coefficients by dividing them with  
865 mean per-SNP heritability as reported by a previous report<sup>26</sup>; we then reported normalized  
866 coefficients. In a fixed-effect meta-analysis of the two results, we used the inverse variance weighting  
867 method using normalized coefficients and their S.E. We reported *P* values to test whether the  
868 regression coefficient is significantly positive.

869 To call HC-SEG (specifically expressed genes in HC) for each cell type, we compared the  
870 expression data of one cell type with that of the remaining cell types that belong to other cell lineages  
871 using the GLM with negative binomial distribution in edgeR (v3.32.1)<sup>65</sup>. To be in line with previous  
872 studies of S-LDSC, only the samples from HC were used in this analysis.

873

#### 874 **GWAS candidate genes enrichment analysis**

875 The SLE-GWAS results were downloaded from the NHGRI-EBI GWAS Catalog<sup>76</sup> on 16/08/2021.

876 Among them, we defined the genes nearest to SLE-GWAS significant variants ( $P < 5 \times 10^{-8}$ ) as

877 GWAS candidate genes (**Supplementary Table 14**). Gene symbols were based on UCSC definition.

878 To test the enrichment of GWAS candidate genes for disease-state and activity signature genes, we

879 performed over-representation analyses with one-sided Fisher's exact test (**Fig. 7b**). We set the



880 union of the genes that passed the filtering of low expression in each cell type and used it as the  
881 background.

882

### 883 **Integrative analysis with eQTL data**

884 To compare the direction between the risk allele's expression quantitative trait loci (eQTL) effects and  
885 disease-state and activity signature genes, we utilized the results of the colocalization test between  
886 SLE-GWAS and ImmuNexUT eQTL data reported in Ota *et al*<sup>27</sup>. For visualization, logFC sign  
887 information was adjusted so that the direction of the coherent genes, which showed the concordant  
888 direction between eQTL effects for risk alleles and differential expressions<sup>56</sup> (**Fig. 7e**), was positive  
889 (i.e., adjusted logFC).

890 To examine the interactive effects of the signature genes on the eQTL effects of SLE risk  
891 variants, we fitted the eGene expressions to the following linear regression models for each cell type  
892 (**Fig. 7f**):

$$893 \text{ Full: } y = \rho \cdot G[0,1,2] + \mu \cdot x + \beta \cdot G : x + \sum_{k=1,2,3} \gamma \cdot I_k[0,1] + \delta \cdot PSL[mg] + \varepsilon \cdot Age[yr] + \epsilon \cdot Sex[0,1] + \theta$$

$$894 \text{ Null: } y = \rho \cdot G[0,1,2] + \mu \cdot x + \sum_{k=1,2,3} \gamma \cdot I_k[0,1] + \delta \cdot PSL[mg] + \varepsilon \cdot Age[yr] + \epsilon \cdot Sex[0,1] + \theta$$

895 Here,  $y$  and  $x$  represents the expression of eGene and pGene, respectively, and  $G$   
896 represents the genotype of each individual.  $I_k (k = 1,2,3)$  represents each immunosuppressant  
897 (MMF, HCQ, TAC) as covariates. We tested the significance of interaction terms (i.e.,  $G : x$ ) by  
898 comparing full and null models using analysis of variance (ANOVA). Statistical significance was set at  
899 FDR < 0.05.

900

901 **Data availability**

902 All analysis results including DEG list and PC loading scores are available as supplementary table  
903 and data. RNA-seq data used in this study will be available at the National Bioscience Database  
904 Center (NBDC) Human Database (Dataset ID: JGAS000486) upon acceptance.

905

906 **Code availability**

907 Codes utilized in this study are available on GitHub (<https://github.com/MasahiroNakano-hub>).

908

909 **Acknowledgments**

910 The super-computing resource was provided by Human Genome Center, Institute of Medical  
911 Sciences, The University of Tokyo (<http://sc.hgc.jp/shirokane.html>). This study was supported by  
912 Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, the Ministry of Education, Culture, Sports, and the  
913 Japan Agency for Medical Research and Development (AMED) (JP21tm0424221 and  
914 JP21zf0127004). We appreciate all SLE patients and HC volunteers who participated in this study.  
915 We would like to thank all collaborators in the University of Tokyo, National Center for Global Health  
916 and Medicine, St. Luke's International Hospital, and Chugai Pharmaceutical Co., Ltd for the  
917 contribution to sample collection and processing. M.N. and K.I. thank Michihiro Kono for helpful  
918 feedback. H. Suetsugu is supported by Practical Research Project for Rare/Intractable Diseases from  
919 Japan AMED. X.Y. is supported by Distinguished Young Scholar of Provincial Natural Science

920 Foundation of Anhui (1808085J08). S. Bae is supported by Basic Science Research Program through  
921 the National Research Foundation of Korea funded by the Ministry of Education (NRF-  
922 2021R1A6A1A03038899).

923

924 **Author contributions**

925 M.N. and K.I. conceived and designed the study. M.N. and K.I. wrote the manuscript with critical  
926 inputs from M.O. and K.F. M.N. conducted all analyses with the help of K.I. M.N., M.O., Y.T., Y.I.,  
927 H.H., Y.N., T.I., J.M., R.Y., S.Y., A.N., Haruka T., Hideyuki T., Y.A., T.K., and H. Shoda managed and  
928 contributed to sample collection and processing. M.O., H.H., Y.N., and T.I. contributed to QC of the  
929 RNA-seq data. H. Suetsugu, L.L., K.K., X.Y., S. Bang, Y.C., H.L., X.Z., S. Bae, and C.T. managed  
930 and contributed to sample collection of EAS SLE-GWAS data. K.Y., T.O., and K.F. designed and  
931 managed the project. All authors contributed to the final version of the manuscript.

932

933 **Competing interests**

934 M.O., Y.T., Y.N., and T.O. belong to the Social Cooperation Program, Department of functional  
935 genomics and immunological diseases, supported by Chugai Pharmaceutical. K.F. receives  
936 consulting honoraria and research support from Chugai Pharmaceutical.

937

938 **Reference**

- 939 1. Liu, Z. & Davidson, A. Taming lupus-a new understanding of pathogenesis is leading to clinical  
940 advances. *Nat. Med.* **18**, 871–882 (2012).
- 941 2. Tsokos, G. C., Lo, M. S., Reis, P. C. & Sullivan, K. E. New insights into the  
942 immunopathogenesis of systemic lupus erythematosus. *Nat. Rev. Rheumatol.* **12**, 716–730  
943 (2016).
- 944 3. Durcan, L., O'Dwyer, T. & Petri, M. Management strategies and future directions for systemic  
945 lupus erythematosus in adults. *Lancet* **393**, 2332–2343 (2019).
- 946 4. Cho, J. H. & Feldman, M. Heterogeneity of autoimmune diseases: Pathophysiologic insights  
947 from genetics and implications for new therapies. *Nat. Med.* **21**, 730–738 (2015).
- 948 5. Wallace, D. J. The evolution of drug discovery in systemic lupus erythematosus. *Nat. Rev.*  
949 *Rheumatol.* **11**, 616–620 (2015).
- 950 6. Navarra, S. V. *et al.* Efficacy and safety of belimumab in patients with active systemic lupus  
951 erythematosus: A randomised, placebo-controlled, phase 3 trial. *Lancet* **377**, 721–731 (2011).
- 952 7. Furie, R. *et al.* A phase III, randomized, placebo-controlled study of belimumab, a monoclonal  
953 antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.  
954 *Arthritis Rheum.* **63**, 3918–3930 (2011).
- 955 8. Furie, R. A. *et al.* Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus  
956 (TULIP-1): a randomised, controlled, phase 3 trial. *Lancet Rheumatol.* **1**, e208–e219 (2019).

- 957 9. Morand, E. F. *et al.* Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N. Engl. J.*  
958 *Med.* **382**, 211–221 (2020).
- 959 10. Bennett, L. *et al.* Interferon and granulopoiesis signatures in systemic lupus erythematosus  
960 blood. *J. Exp. Med.* **197**, 711–723 (2003).
- 961 11. Baechler, E. C. *et al.* Interferon-inducible gene expression signature in peripheral blood cells of  
962 patients with severe lupus. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 2610–2615 (2003).
- 963 12. Kirou, K. A. *et al.* Activation of the interferon- $\alpha$  pathway identifies a subgroup of systemic lupus  
964 erythematosus patients with distinct serologic features and active disease. *Arthritis Rheum.* **52**,  
965 1491–1503 (2005).
- 966 13. Banchereau, R. *et al.* Personalized Immunomonitoring Uncovers Molecular Networks that  
967 Stratify Lupus Patients. *Cell* **165**, 551–565 (2016).
- 968 14. El-Sherbiny, Y. M. *et al.* A novel two-score system for interferon status segregates  
969 autoimmune diseases and correlates with clinical features. *Sci. Rep.* **8**, 1–11 (2018).
- 970 15. Catalina, M. D., Bachali, P., Geraci, N. S., Grammer, A. C. & Lipsky, P. E. Gene expression  
971 analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus.  
972 *Commun. Biol.* **2**, (2019).
- 973 16. Panousis, N. I. *et al.* Combined genetic and transcriptome analysis of patients with SLE:  
974 distinct, targetable signatures for susceptibility and severity. *Ann. Rheum. Dis.* **78**, 1079–1089  
975 (2019).

- 976 17. Lyons, P. A. *et al.* Novel expression signatures identified by transcriptional analysis of  
977 separated leucocyte subsets in systemic lupus erythematosus and vasculitis. *Ann. Rheum.*  
978 *Dis.* **69**, 1208–1213 (2010).
- 979 18. Der, E. *et al.* Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis  
980 reveal type I IFN and fibrosis relevant pathways. *Nat. Immunol.* **20**, 915–927 (2019).
- 981 19. Arazi, A. *et al.* The immune cell landscape in kidneys of patients with lupus nephritis. *Nat.*  
982 *Immunol.* **20**, 902–914 (2019).
- 983 20. Nehar-Belaid, D. *et al.* Mapping systemic lupus erythematosus heterogeneity at the single-cell  
984 level. *Nat. Immunol.* **21**, 1094–1106 (2020).
- 985 21. Bentham, J. *et al.* Genetic association analyses implicate aberrant regulation of innate and  
986 adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat. Genet.*  
987 **47**, 1457–1464 (2015).
- 988 22. Langefeld, C. D. *et al.* Transancestral mapping and genetic load in systemic lupus  
989 erythematosus. *Nat. Commun.* **8**, (2017).
- 990 23. Yin, X. *et al.* Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic  
991 lupus erythematosus. *Ann. Rheum. Dis.* **80**, 632–640 (2021).
- 992 24. Westra, H. J. *et al.* Systematic identification of trans eQTLs as putative drivers of known  
993 disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).
- 994 25. Farh, K. K. H. *et al.* Genetic and epigenetic fine mapping of causal autoimmune disease  
995 variants. *Nature* **518**, 337–343 (2015).

- 996 26. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-  
997 relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
- 998 27. Ota, M. *et al.* Dynamic landscape of immune cell-specific gene regulation in immune-mediated  
999 diseases. *Cell* **184**, 3006–3021.e17 (2021).
- 1000 28. Gladman, D. D., Ibañez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity  
1001 index 2000. *J. Rheumatol.* **29**, 288–91 (2002).
- 1002 29. Isenberg, D. A. *et al.* BILAG 2004. Development and initial validation of an updated version of  
1003 the British Isles Lupus Assessment Group’s disease activity index for patients with systemic  
1004 lupus erythematosus. *Rheumatology* **44**, 902–906 (2005).
- 1005 30. Banchereau, J. & Pascual, V. Type I Interferon in Systemic Lupus Erythematosus and Other  
1006 Autoimmune Diseases. *Immunity* **25**, 383–392 (2006).
- 1007 31. Elkon, K. B. & Stone, V. V. Type I interferon and systemic lupus erythematosus. *J. Interf.*  
1008 *Cytokine Res.* **31**, 803–812 (2011).
- 1009 32. Crow, M. K. Type I Interferon in the Pathogenesis of Lupus. *J. Immunol.* **192**, 5459–5468  
1010 (2014).
- 1011 33. Panwar, B. *et al.* Multi-cell type gene coexpression network analysis reveals coordinated  
1012 interferon response and cross-cell type correlations in systemic lupus erythematosus.  
1013 *Genome Res.* **31**, 659–676 (2021).

- 1014 34. Andreoletti, G. *et al.* Transcriptomic analysis of immune cells in a multi-ethnic cohort of  
1015 systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression  
1016 signatures. *Commun. Biol.* **4**, 1–13 (2021).
- 1017 35. Takeshima, Y. *et al.* Immune cell multi-omics analysis reveals contribution of oxidative  
1018 phosphorylation to B cell functions and organ damage of lupus. *bioRxiv* (2021)  
1019 doi:<https://doi.org/10.1101/2021.10.08.463629>.
- 1020 36. Uzhachenko, R. V. & Shanker, A. CD8+ T lymphocyte and NK cell network: Circuitry in the  
1021 cytotoxic domain of immunity. *Front. Immunol.* **10**, 1–7 (2019).
- 1022 37. Dean, G. S., Tyrrell-Price, J., Crawley, E. & Isenberg, D. A. Cytokines and systemic lupus  
1023 erythematosus. *Ann. Rheum. Dis.* **59**, 243–51 (2000).
- 1024 38. Theofilopoulos, A. N., Koundouris, S., Kono, D. H. & Lawson, B. R. The role of IFN-gamma in  
1025 systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. *Arthritis*  
1026 *Res.* **3**, 136–41 (2001).
- 1027 39. Harigai, M. *et al.* Excessive Production of IFN- $\gamma$  in Patients with Systemic Lupus  
1028 Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating  
1029 Factor/TNF Ligand Superfamily-13B. *J. Immunol.* **181**, 2211–2219 (2008).
- 1030 40. Vincent, F. B., Morand, E. F., Schneider, P. & MacKay, F. The BAFF/APRIL system in SLE  
1031 pathogenesis. *Nat. Rev. Rheumatol.* **10**, 365–373 (2014).
- 1032 41. Wang, S. *et al.* IL-21 drives expansion and plasma cell differentiation of autoreactive  
1033 CD11c<sup>hi</sup>T-bet<sup>+</sup> B cells in SLE. *Nat. Commun.* **9**, 1–14 (2018).



- 1034 42. Rao, D. A. T cells that help B cells in chronically inflamed tissues. *Front. Immunol.* **9**, (2018).
- 1035 43. Crotty, S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. *Immunity* **50**,
- 1036 1132–1148 (2019).
- 1037 44. Kometani, K. *et al.* Repression of the Transcription Factor Bach2 Contributes to Predisposition
- 1038 of IgG1 Memory B Cells toward Plasma Cell Differentiation. *Immunity* **39**, 136–147 (2013).
- 1039 45. Sidwell, T. *et al.* Attenuation of TCR-induced transcription by Bach2 controls regulatory T cell
- 1040 differentiation and homeostasis. *Nat. Commun.* **11**, 1–17 (2020).
- 1041 46. Cook, H. T. & Botto, M. Mechanisms of Disease: the complement system and the
- 1042 pathogenesis of systemic lupus erythematosus. *Nat. Clin. Pract. Rheumatol.* **2**, 330–337
- 1043 (2006).
- 1044 47. Leffler, J., Bengtsson, A. A. & Blom, A. M. The complement system in systemic lupus
- 1045 erythematosus: An update. *Ann. Rheum. Dis.* **73**, 1601–1606 (2014).
- 1046 48. Gupta, S. & Kaplan, M. J. The role of neutrophils and NETosis in autoimmune and renal
- 1047 diseases. *Nat. Rev. Nephrol.* **12**, 402–413 (2016).
- 1048 49. Kuriakose, J. *et al.* Patrolling monocytes promote the pathogenesis of early lupus-like
- 1049 glomerulonephritis. *J. Clin. Invest.* **129**, 2251–2265 (2019).
- 1050 50. Sun, S. C. The non-canonical NF- $\kappa$ B pathway in immunity and inflammation. *Nat. Rev.*
- 1051 *Immunol.* **17**, 545–558 (2017).
- 1052 51. McAllister, E. & Jellusova, J. BAFF signaling in B cell metabolism. *Curr. Opin. Immunol.* **71**,
- 1053 69–74 (2021).

- 1054 52. Jonsson, C. A. & Carlsten, H. Mycophenolic acid inhibits inosine 5'-monophosphate  
1055 dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. *Int.*  
1056 *Immunopharmacol.* **3**, 31–37 (2003).
- 1057 53. Gatto, M., Zen, M., Iaccarino, L. & Doria, A. New therapeutic strategies in systemic lupus  
1058 erythematosus management. *Nat. Rev. Rheumatol.* **15**, 30–48 (2019).
- 1059 54. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide  
1060 association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
- 1061 55. Amariuta, T. *et al.* Improving the trans-ancestry portability of polygenic risk scores by  
1062 prioritizing variants in predicted cell-type-specific regulatory elements. *Nat. Genet.* **52**, 1346–  
1063 1354 (2020).
- 1064 56. Marigorta, U. M. *et al.* Transcriptional risk scores link GWAS to eQTLs and predict  
1065 complications in Crohn's disease. *Nat. Genet.* **49**, 1517–1521 (2017).
- 1066 57. Zhernakova, D. V. *et al.* Identification of context-dependent expression quantitative trait loci in  
1067 whole blood. *Nat. Genet.* **49**, 139–145 (2017).
- 1068 58. Van Vollenhoven, R. F. *et al.* Treat-to-target in systemic lupus erythematosus:  
1069 Recommendations from an international task force. *Ann. Rheum. Dis.* **73**, 958–967 (2014).
- 1070 59. Franklyn, K. *et al.* Definition and initial validation of a Lupus Low Disease Activity State  
1071 (LLDAS). *Ann. Rheum. Dis.* **75**, 1615–1621 (2016).
- 1072 60. Fanouriakis, A. *et al.* 2019 Update of the EULAR recommendations for the management of  
1073 systemic lupus erythematosus. *Ann. Rheum. Dis.* **78**, 736–745 (2019).

- 1074 61. Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the  
1075 classification of systemic lupus erythematosus. *Arthritis and rheumatism* vol. 40 1725 (1997).
- 1076 62. Maecker, H. T., McCoy, J. P. & Nussenblatt, R. Standardizing immunophenotyping for the  
1077 Human Immunology Project. *Nat. Rev. Immunol.* **12**, 191–200 (2012).
- 1078 63. Dobin, A. *et al.* STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 1079 64. Anders, S., Pyl, P. T. & Huber, W. HTSeq-A Python framework to work with high-throughput  
1080 sequencing data. *Bioinformatics* **31**, 166–169 (2015).
- 1081 65. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for  
1082 differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140  
1083 (2009).
- 1084 66. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data  
1085 using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
- 1086 67. Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects models using  
1087 lme4. *J. Stat. Softw.* **67**, (2015).
- 1088 68. McInnes, L., Healy, J., Saul, N. & Großberger, L. UMAP: Uniform Manifold Approximation and  
1089 Projection. *J. Open Source Softw.* **3**, 861 (2018).
- 1090 69. Hoffman, G. E. & Schadt, E. E. variancePartition: Interpreting drivers of variation in complex  
1091 gene expression studies. *BMC Bioinformatics* **17**, 17–22 (2016).
- 1092 70. Liu, Z. *et al.* Multitarget therapy for induction treatment of lupus nephritis: A randomized trial.  
1093 *Ann. Intern. Med.* **162**, 18–26 (2015).

- 1094 71. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: An R package for comparing  
1095 biological themes among gene clusters. *Omi. A J. Integr. Biol.* **16**, 284–287 (2012).
- 1096 72. Kolmykov, S. *et al.* Gtrd: An integrated view of transcription regulation. *Nucleic Acids Res.* **49**,  
1097 D104–D111 (2021).
- 1098 73. Liberzon, A. *et al.* The Molecular Signatures Database Hallmark Gene Set Collection. *Cell*  
1099 *Syst.* **1**, 417–425 (2015).
- 1100 74. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids*  
1101 *Res.* **28**, 27–30 (2000).
- 1102 75. Stohl, W. *et al.* Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus  
1103 Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.  
1104 *Arthritis Rheumatol.* **69**, 1016–1027 (2017).
- 1105 76. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association  
1106 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005–D1012  
1107 (2019).

1108